RNF139

RNF139 Full Name

ring finger protein 139

RNF139 Introduction

RNF139 (ring finger protein 139), also known as TRC8, is an unusual E3 ubiquitin ligase that spans the endoplasmic reticulum membrane and couples protein ubiquitylation to the sensing of lipid and cholesterol status. TRC8 was originally discovered through a constitutional chromosome translocation, t(3;8)(p14;q24), that predisposes to hereditary renal cell carcinoma, and subsequent analysis revealed that the gene encodes a multitransmembrane protein whose N-terminal RING finger faces the cytoplasm while its membrane-spanning region contains a sterol-sensing domain, a module otherwise found in regulators of cholesterol homeostasis such as HMG-CoA reductase and SCAP. This domain architecture immediately suggested that TRC8 could translate sterol levels into the ubiquitin-dependent destruction of specific target proteins, and functional studies have indeed connected it to ER-associated degradation and to the control of lipid-related transcription factors. Germline loss-of-function mutations of RNF139 confer a markedly increased risk of renal cancer, indicating that the protein acts as a tumor suppressor in the kidney. More recent work has expanded the picture to include roles in cholesterol metabolism, developmental signaling, and the ERAD pathway, making TRC8 a fascinating example of how metabolic sensing and protein quality control converge at the ER membrane.

Figure 1. RNF139:gene & functional roles of trc8 protein.

Transmembrane Topology, Sterol Sensing, and RING-Dependent Ubiquitylation
The RNF139 protein is embedded in the endoplasmic reticulum membrane through multiple hydrophobic segments, with its catalytic RING-H2 finger exposed to the cytosol where it can recruit E2 ubiquitin-conjugating enzymes.
Between the transmembrane spans lies a sterol-sensing domain, a conserved structural module that detects cholesterol or oxysterol levels and is shared with HMG-CoA reductase and SCAP, the master regulator of SREBP processing.
The RNF139 gene resides on human chromosome 8 at band q24, within a genomic region recurrently altered in renal and other cancers.
As an ER-resident RING E3 ligase, TRC8 participates in ER-associated degradation, the pathway that polices membrane and secretory proteins by retrotranslocating misfolded or surplus proteins to the cytosol for proteasomal destruction.
Ubiquitin ligases of this class typically ubiquitylate their substrates and thereby destine them for the proteasome, and TRC8 has been shown to associate with components of the ERAD machinery.
The combination of a sterol-sensing domain and an E3 ligase activity is believed to allow TRC8 to couple the cellular lipid environment to the ubiquitylation of lipid-regulated or lipid-sensing proteins.
Additional protein-interaction surfaces link TRC8 to signaling pathways, and its activity is controlled by regulated degradation of the ligase itself.

Tumor Suppression in the Kidney, Cholesterol Crosstalk, and ERAD Functions
The initial identification of RNF139 as a gene disrupted by the t(3;8) translocation in a family with hereditary renal cell carcinoma established TRC8 as a kidney tumor suppressor whose inactivation initiates malignant transformation.
Subsequent analyses found RNF139 mutations or loss of expression in sporadic renal cancers and in a range of other tumor types, and reintroduction of the wild-type protein suppresses the growth of cancer cells in experimental models.
The sterol-sensing function of TRC8 connects it to cholesterol homeostasis: the ligase is regulated by sterol levels and, in turn, influences the stability of proteins involved in lipid metabolism, providing a molecular link between metabolic dysregulation and cancer risk.
TRC8 also functions within the ERAD quality-control network, and loss of the protein compromises the cell's ability to dispose of certain aberrant membrane proteins.
Because cholesterol metabolism is frequently rewired in cancer, the tumor-suppressive activity of TRC8 may reflect, at least in part, its capacity to restrain the lipid-driven growth signals that support malignant cells.
Therapeutic strategies aimed at reactivating TRC8 function or at exploiting the vulnerabilities created by its loss are in the earliest stages of exploration, but the gene's clear role in renal cancer makes it a high-priority target for future study.

Alternate Names for RNF139

RNF139; ring finger protein 139; E3 ubiquitin-protein ligase RNF139; HRCA1; RCA1; TRC8; multiple membrane spanning receptor TRC8; patched related protein translocated in renal cancer; translocation in renal carcinoma on chromosome 8 protein; MGC31961;